ISCT22: Antion Biosciences CEO highlights new way of approaching allogeneic cell creation

May 9, 2022

Dr. Sven Kili, CEO of Antion Biosciences, contends the Swiss company's microRNA (miRNA) technology (miCAR platform) is a new way of approaching allogeneic cell creation by enabling simultaneous silencing of multiple gene targets while overcoming the challenges faced by existing gene editing approaches.

"The miCAR platform allows us to move beyond gene editing into an ability to silence up to six different genes," Kili told ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco. "What this does is makes incredibly powerful cells in a very simple, easy way, which has a much lower cost of goods but a much higher ability to have quality cells."

Kili, who is chair of the ISCT 2022 Business Models & Investment Subcommittee and co-chair of the annual meeting, said Antion Biosciences is starting out with a proof-of-concept involving the miCAR platform's use in creating allogeneic T cells with a first indication in T cell malignancies. The company will then progress to solid tumors.

Watch the video below to learn more.


ISCT22: BroadOak’s Poltilove remains bullish on CGT market despite downturn
Bryan Poltilove, partner at BroadOak Capital Partners, spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT)...
ISCT22: Orgenesis looks to simplify, lower costs of providing CGT therapies
Personalized cell and gene therapies (CGTs) offer the potential to address the most challenging diseases, Vered Caplan, CEO of biotech company Orgenesis,...
ISCT22: Children's National sees improved cell therapy potency, quicker patient delivery
Children's National Hospital in Washington, DC, is seeing improvements in the potency of existing cell therapies and a reduction in the time it takes...
ISCT president calls for cell and gene therapy education, training amid ‘talent shortage’
This week in San Francisco, industry, investors, physicians, patients, and regulators convened at the International Society for Cell & Gene Therapy (ISCT)...
ISCT working group weighs in on expanded access to CGT
Patricia Zettler, JD, associate professor of law at The Ohio State University, and chair of the International Society for Cell & Gene Therapy (ISCT) Expanded...
ISCT22: Cell therapy has potential to address unmet medical needs in orthopedics
Miguel Forte, CEO of Bone Therapeutics, and president-elect of the International Society for Cell & Gene Therapy (ISCT), spoke with ScienceBoard.net...
ISCT22: Tackling the ethical issues around cell and gene therapy
Unproven and unethical cell and gene therapies are a growing problem worldwide, according to Laertis Ikonomou, PhD, of the Department of Oral Biology...

Copyright © 2022 scienceboard.net

Last Updated 5/9/2022 8:10:57 AM